{"title": "Amid Novartis spinoff efforts, Sandoz pledges $400M for biosimilar manufacturing in Slovenia", "author": "Eric Sagonowsky", "url": "https://www.fiercepharma.com/manufacturing/amid-novartis-spinoff-sandoz-pledges-400m-biosimilar-manufacturing-slovenia", "hostname": "fiercepharma.com", "description": "Novartis may be in the process of spinning out its generics and biosimilar outfit, Sandoz, but that doesn't mean the latter company is pausing manufacturing investments. | Novartis may be in the process of spinning out its generics and biosimilar outfit, Sandoz, but that doesn't mean the latter company is pausing manufacturing investments. The generics and biosimilar player revealed plans for a $400 million plant in Slovenia.", "sitename": "FiercePharma", "date": "2023-03-10", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}